Crystallization and preliminary crystallographic analysis of a novel cytochrome P450 from Mycobacterium tuberculosis

CG Mowat, D Leys, KJ McLean, SL Rivers, A Richmond, AW Munro, MO Lombardia, PM Alzari, GA Reid, Stephen K. Chapman, MD Walkinshaw*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Abstract

The product of the Rv2276 gene of Mycobacterium tuberculosis is a cytochrome P450 (P450 MT2, CYP121) which has been shown to bind tightly to a range of azole-based antifungal drugs (e.g. miconazole, clotrimazole). These drugs are potent inhibitors of mycobacterial growth, suggesting that P450 MT2 (CYP121) may be a potential drug target. The enzyme has been overexpressed in Escherichia coli and crystallized by the hanging-drop method. Crystals of P450 MT2 (CYP121) belong to the hexagonal space group P6(1)22 or P6(5)22, with unit-cell parameters a = b = 78.3, c = 265.6 Angstrom. Native data have been collected to 1.6 Angstrom resolution and Hg-derivative data to 2.5 Angstrom resolution using a synchrotron-radiation source.

Original languageEnglish
Pages (from-to)704-705
Number of pages2
JournalActa crystallographica. Section D, Biological crystallography
Volume58
DOIs
Publication statusPublished - Apr 2002

Fingerprint

Dive into the research topics of 'Crystallization and preliminary crystallographic analysis of a novel cytochrome P450 from Mycobacterium tuberculosis'. Together they form a unique fingerprint.

Cite this